Form 8-K - Current report:
SEC Accession No. 0001641172-25-008836
Filing Date
2025-05-06
Accepted
2025-05-06 16:05:31
Documents
19
Period of Report
2025-05-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47861
2 EX-2.1 ex2-1.htm EX-2.1 393959
3 EX-99.1 ex99-1.htm EX-99.1 25758
4 GRAPHIC form8-k_001.jpg GRAPHIC 5694
5 GRAPHIC ex99-1_001.jpg GRAPHIC 54048
  Complete submission text file 0001641172-25-008836.txt   854635

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cycc-20250506.xsd EX-101.SCH 3743
7 XBRL DEFINITION FILE cycc-20250506_def.xml EX-101.DEF 26581
8 XBRL LABEL FILE cycc-20250506_lab.xml EX-101.LAB 36613
9 XBRL PRESENTATION FILE cycc-20250506_pre.xml EX-101.PRE 25205
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5750
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25917199
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)